COVID-19 vaccine effectiveness
(Randomized evidence)

If you want to see all comparisons, please click here

BNT/ChA-28 vs BNT/BNT-28

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots
(last update: 2021-07-15)

Evidence profile
2021-07-26

Summary of findings
2021-07-26

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
ISRCTN69254139, EudraCT: 2020-005085-33
AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma
Liu X, SSRN, 2021
Com-COV

Full text
Commentary
Commentary
Commentary
Commentary
RNA based vaccine

ChAd/ChAd-28

BNT/BNT-28

ChAd/BNT-28

BNT/ChAd-28

RCT
Phase 2
Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK N=463
Some concerns
Details

Full description